Table 1 Drugs targeting protein kinases involved in neurodegenerative disease in clinical trials (can be found at https://clinicaltrials.gov/)

From: Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery

NCT Number	Compound	Target	Conditions	Phase	Status	Combination Therapy
NCT05194163	MW150	p38αMAPK^583,584,585	Alzheimer’s disease	phase II	Not yet recruiting	None
NCT02423200	VX-745	p38αMAPK⁵⁸⁶	Alzheimer’s disease	phase II	Completed	None
NCT02423122	VX-745	p38αMAPK⁵⁸⁶	Alzheimer’s disease Mild cognitive impairment	phase II	Completed	None
NCT03402659	Neflamapimod	p38αMAPK⁵⁸⁶	Alzheimer’s disease	phase II	Completed	None
NCT00088387	Lithium	GSK3^598,599,600	Alzheimer’s disease	phase II	Completed	Divalproex
NCT00948259	NP031112	GSK3β⁵⁹²	Alzheimer’s disease	phase I/II	Completed	None
NCT01055392	Lithium Carbonate	GSK3⁵⁹⁸	Cognitive Impairment Alzheimer’s disease	phase II	Unknown	None
NCT05564169	Masitinib (4.5)	Tyrosine kinase⁶¹⁰	Mild to moderate Alzheimer’s disease	phase III	Recruiting	Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
NCT05143528	Nilotinib BE (84 mg or 112 mg)	Tyrosine kinase⁶¹⁰	Early Alzheimer’s disease	phase III	Not yet recruiting	None
NCT01872598	Masitinib	Tyrosine kinase⁶¹⁰	Mild to moderate Alzheimer’s disease	phase III	Completed	Cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine
NCT00606164	Bryostatin 1	Protein kinase C⁶¹⁶	Alzheimer’s disease	phase II	Unknown status	None
NCT02167256	AZD0530 (100 or 125 mg daily)	Src family kinases (SFKs)-Fyn⁶¹⁴	Alzheimer’s disease	phase II	Completed	None
NCT01699711	Epigallocatechin-3gallate	Dyrk1A and APP⁶²⁰	Down syndrome	phase II	Completed	Dietary supplement
NCT Number	Compound	Target	Conditions	Phase	Status	Combination Therapy
NCT05189106	Baricitinib	JAK1/2⁶²¹	Amyotrophic lateral sclerosis Alzheimer disease Mild cognitive impairment	phase I/II	Recruiting	None
NCT03655236	K0706	Abl Tyrosine kinase³⁶⁴	Early Parkinson’s disease	phase II	Recruiting	None
NCT00095355	Lithium	Tyrosine kinase and ERK⁶²⁷	Huntington’s disease	phase II	Completed	Divalproex
NCT03792490	Fasudil	Rho kinase (ROCK)^556,557	Amyotrophic lateral sclerosis	phase II	Completed	None
NCT05218668	WP-0512	ROCK^556,557	Amyotrophic lateral sclerosis	phase II	Active, not recruiting	None
NCT01935518	Fasudil	ROCK^556,557	Amyotrophic lateral sclerosis	phase II	Unknown status	None
NCT03127267	Masitinib (6.0) Masitinib (4.5)	Tyrosine kinase⁶³⁵	Amyotrophic lateral sclerosis	phase III	Recruiting	Riluzole
NCT04326283	Trametinib (0.5 mg) Trametinib (1 mg)	MEK⁶⁴⁰	Amyotrophic lateral sclerosis	phase I/II	Recruiting	Riluzole
NCT05105958	Tideglusib (NP031112) (1000 mg/day)	GSK3β⁶⁴⁶	Amyotrophic lateral sclerosis	phase II	Not yet recruiting	None
NCT03932669	Nilotinib	Bcr-Abl⁵⁷⁵	Spinocerebellar ataxia	phase II	Completed	None
NCT06065046	Baricitinib (4 mg)	JAK1 and JAK2⁵⁸¹	Traumatic brain injury	phase II	Not yet recruiting	Standard treatment

Back to article page

Table 1 Drugs targeting protein kinases involved in neurodegenerative disease in clinical trials (can be found at https://clinicaltrials.gov/)

Search

Quick links